Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a dismal prognostic. KRAS is a well-recognized driver gene in PDAC, detected in the earliest stages of pancreatic tumor transformation. To establish the frequency of KRAS mutations in a cohort of Romanian patients, we performed Sanger sequencing for exon 2 and exon 3 of the gene on 31 PDACs pairs. We further examined correlation of the mutational status with clinico-pathologic data of the patients and evaluated the prognostic implication of KRAS mutations. Ten out of 31 patients (32%) had KRAS missense mutations, all were detected in exon 2, and codon 12 only. Among patients with KRAS mutations, the majority (7/10, 70%) had c.35G>A (p.G12D) substitutions. Patients with p.G12D mutations had a marginally worse survival (p=0.07) and a shorter disease-free survival (p=0.04) when compared to KRAS wild-type patients. Correlation between patients age and recurrence was seen in KRAS wild-type cohort (p=0.096, r=-0.6). In summary, evaluation of KRAS mutational status is a predictor for PDAC patients` prognosis and further KRAS directed therapy might prove to be an efficient tool in patients having KRAS mutations.
INTRODUCTION INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) remains the malignancy with one of the highest mortality rate among solid tumors (1) . In the majority of cases (80-90%) the cancer is diagnosed in late stages while in the remaining, even the surgical intervention is a viable choice, local and systemic recurrence if often seen (2) .
PDAC is characterized by an extensive stromal involvement and a variety of genetic and epigenetic events (3) . Four genes are considered as driver gene or "mountains" (4) in PDAC: one oncogene, KRAS, and three tumor suppressor genes, TP53, p16/CDKN2A and SMAD4 (5) .
KRAS is a small GTPase, a switch between GTPbound active and GDP inactive states. Mutation in KRAS found in more than 90% of PDAC cases, maintains a constitutive active state of the gene and a constant stimulation of down-stream pathways (6) like Raf/Mek/ Erk, PI3K/Pdk1/Akt and the Ral guanine nucleotide exchange factor pathway (7, 8, 9, 10) . This stimulation further leads to manifestation of the very well-known features of cancer: increased proliferation, suppression of apoptosis, alteration in the tumors microenvironment, evasion to chemotherapeutic drugs and metastasis (11) .
The majority of KRAS mutations are point mutations, found in exon 2, codon 12 of the gene that determines a switch between amino acid glycine (G) with amino acid aspartic acid (D). Compared to other cancer (eg. colorectal cancer, non-small cell lung cancer), this type of activating mutation is found at a very high frequency in PDAC (12, 13) .
Considering the high frequency of KRAS mutation reported so far in PDAC, we aimed in determining the incidence of mutations in a lot of Romanian patients and further to determine correlation with clinic-pathological features of the patients, overall survival and disease-free survival.
MATERIALS AND METHODS MATERIALS AND METHODS

Patients' samples
Based on an informed written consent, samples of pancreatic duodenal adenocarcinoma from 31 patients who underwent surgical resection were obtained from the Centre of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute. Histological diagnosis was established by a general pathologist.
Length of follow-up, time to recurrence, the time to death was calculated in months from the date of surgery for each patient.
DNA samples
Genomic DNA was extracted from pairs of normal and tumoral frozen tissue by means of Qiagen Blood and Cell Culture Mini Kit (Hilden, Germany), a column based kit,according to manufacturer's instructions.The genomic DNA was bound to column, washed, eluted and quantified using spectrophotometry. Integrity was checked by running 200 ng of genomic DNA on 0.8% agarose gel.
KRAS mutations by Sanger sequencing
Genomic DNA was amplified with Illustra GenomPhi HY DNA Amplification Kit (GE healthcare, Buckinghamshire, UK) and Platinum Taq Polymerase (Life technologies, Carlsbad, USA) was used for PCR reaction using the following program: 95°C for 10 minute; 39 cycles of 95°C for 30seconds; 60°C for 30 seconds, 72°C for 1 minute and a final extension of 72°C for 10 min. Purified PCR products were sequenced with ABI BigDye Terminator v3.1 (Life technologies, Carlsbard, USA) following manufacturer's protocol and ran on an ABI 3730 genetic analyzer. The results were analyzed using Seqman II DNAstar (v.5.05) (Madison, Wisconsin, USA) and Chromas 2.4.3 (South Brisbane, Australia). The primers used to perform PCR and Sanger sequencing are the ones previously described (14) .
Statistical analysis
Dichotomous variables were evaluated using Fisher's exact test or Pearson's χ 2 . Differences between groups were evaluated by means of nonparametric Mann-Whitney or Kruskal-Wallis test. Survival analyses were performed using the Kaplan-Meier curves and the differences in survival curves were assessed byLog rank Mantel Cox test. A p-value ≤ 0.05 was considered statistically significant. All tests were performed with GraphPad Prism 5 (GraphPad Software Inc, San Diego, CA).
RESULTS RESULTS
Clinicopathologic characteristics of the patients
Clinico-pathologic characteristics of all patients are included in table 1. From the total of 31 patients, 13 (42%) received chemotherapy with gemcitabine alone, 13 (42%) received 5-fluorouracil (5-FU) or 5-fluorouracil and cisplatin and one patient (3.2%) received another chemotherapeutic regimen (for four patients the chemotherapeutic regimen received is unknown). Marginal association were observed when comparing overall survival between patients receiving gemcitabine or other chemotherapeutic regimen (median 18 months for gemcitabine versus 9 months for 5-FU/ 5-FU and cisplatin or other chemotherapeutic regimen, p=0.09, long-rank Mantel Cox test) and when comparing overall survival based on CA 19-9 level, using a cut off value of 1000 U/ml (median 18 months, for patients with CA 19-9 levels lower than 1000 U/ml versus 6.5 months, for patients with CA 19-9 levels higher than 1000 U/ml p=0.06, long-rank Mantel Cox test). The majority of patients had no associated diabetes at tumor diagnostic (23/31, 74.2%). A statistically significant difference was seen when comparing patients groups based on lymphnode ratio (LNR), when using a cut off value for LNR of 0.16 (median 21 months for patients with LNR lower than 0.16 versus median 11 months for patients with LNR higher than 0.16, p=0.007, long-rank Mantel Cox test).
KRAS p.G12D mutations shows a marginal association with worse overall-survival and disease-free survival
Detailed description of clinic-pathologic characteristics of patients with KRAS mutation versus KRAS wild type patients is included in table 2. Among the analyzed patients, 10/31 (32%) had KRAS mutations: seven had c.35G>A (p.G12D), two had c.35G>T (p.G12V) and one had c.34G>C (p.G12R) ( fig. 1 a, b and c) . All mutations were in exon2, codon 12 ( fig. 1d) . A marginal association with overall survival was seen when comparing patients with KRAS mutations and KRAS wild-type patients (p=0.075, median of 11.5 months for KRAS mutant patients versus median of 18 months for KRAS wild-type patients). The same trend, of marginal association, was seen when comparing patients with p.G12D mutations only and KRAS wild-type patients (p=0.07, median of 11 months for p.G12D mutations patients versus median of 18 months for KRAS wild-type patients, (fig. 1f) . Analysis on disease-free survival,between patients with p.G12D mutations and KRAS wild-type patients showed a statistically significant difference (p=0.04, fig. 1f ). Additional statistically significant correlations between clinic-pathologic features for patients with p.G12D mutations and KRAS wild-type patients are included in fig. 2 a and b. 
DISCUSSIONS DISCUSSIONS
PDAC is characterized by a complex mutational landscape (15) but is essentially a KRAS oncogenedriven solid tumor (16) .
KRAS is the gene that is almost ubiquitously detected in pancreatic cancer whole exome and genome studies (17, 18) .
It is a protein in the epidermal growth factor receptor (EGFR) signaling pathway whose importance in PDAC progression was shown by multiple mouse model (11, 19, 20, 21, and 22) .
In our study we found the frequency of KRAS somatic mutation of 32%, much lower than the one previously reported for this cancer (23) . One limitation of our current study is that the method of detection used has its own limits (24) which might led to a lower estimation of KRAS mutation frequency.
All detected KRAS point mutations were exclusively in exon 2, codon 12 with the majority (70%) being c.35G>A (p.G12D) substitutions.
We observed trends towards a worse overall survival when analyzing patients with KRAS mutations or p.G12D mutations exclusively and KRAS wild-type patients. A shorter overall survival was seen in patients with p.G12D mutations only compared to wild-type patients.
Further analysis in patients with p.G12D mutations and KRAS wild type patients showed correlation between overall survival and disease-free survival, stage and pN and LNR, disease-free survival and recurrence (in KRAS wild-type patients only) and age and recurrence (in patients with p.G12D mutations only). This is consistent with previous studies showing a poor outcome in patients with p.G12D mutant tumors (25, 26) .
Transcriptomic characterization of PDAC, initially divided it intro three types: quasi-mesenchymal, classic, and exocrine-like (9) and later, the classical subtype was sub-divided into pancreatic progenitor and immunogenic subtype (15 (27) . This studies, once again, shows the importance of evaluation of KRAS status in patients stratification and in precision medicine, respectively. For long time KRAS mutations were considered undruggable, but today new methods of targeting KRAS mutations, with emphasis on p.G12D mutations, are being developed (eg. siG12D-LODER). A phase I/IIa clinical study using this approach in combination with FOLFIRINOX showed a potential efficacy in patients with locally advance pancreatic cancer (28) .
The end results of this technological progress could be an effective treatment options for patients based on their tumor molecular blueprint, and in particular based on the KRAS mutational status.
Our results showed that a classification based on KRAS status has prognostic implications. Taken together with the literature data, these results highlight the importance of both KRAS genomic characterization of PDAC in treatment decision making.
CONCLUSIONS CONCLUSIONS
Our study showed a lower KRAS mutation frequency in PDAC and confirmed the prognostic value of p.G12D mutations on the patients` outcome in this type of cancer. As research is directed into making KRAS to become therapeutically targetable, our results have implication in the field of personalized medicine. Moreover additional research will be needed to further characterize KRAS wild-type patients and to evaluate best therapy options for them.
